title: Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects.
abstract: Doxorubicin (DOX) is one of the most active anticancer drugs, while its cumulative dose-dependent side effects compromise the anticancer efficacy. Nanoparticles, an emerging platform for cancer therapy, have been shown to increase intracellular uptake of DOX with reduced side effects compared with conventional DOX formulations. While large numbers of clinical and preclinical studies have been published, the purpose of this review is to draw attention to the developments of DOX-loaded nanoparticles for cancer therapy, with special a focus on enhanced intracellular uptake and reduced side-effects strategies.
authors: Protein & Peptide Pharmaceutical Laboratory, National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
authors: Yiguang
authors: Y
authors: Wang
authors: Xiuli
authors: X
authors: Wei
authors: Chunling
authors: C
authors: Zhang
authors: Fayun
authors: F
authors: Zhang
authors: Wei
authors: W
authors: Liang
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D001692:Biological Transport; D002626:Chemistry, Pharmaceutical; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D004337:Drug Carriers; D004339:Drug Compounding; D006801:Humans; D050997:Nanomedicine; D053758:Nanoparticles; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011108:Polymers / Q000737:chemistry*; D013678:Technology, Pharmaceutical / Q000379:methods*
chemical_list: D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D011108:Polymers; D004317:Doxorubicin